Summit Therapeutics Inc. SMMT
16.17 USD +0.37 (+2.34%)
At closeNov 4, 2026, 6:41 PM EST
16.07 -0.10 -0.62%
After hours · Nov 4, 6:41 PM ET
15.41 Day range 16.43
12.07 52-week range 29.23
- YTD
- -7.55%
- 1 year
- -7.55%
News
benzinga.com Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 53.85 percent decrease over losses of…
businesswire.com Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update…
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.
marketbeat.com Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their…
fool.com Breakfast News: Science Strikes Back at Cancer Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
gurufocus.com Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
businesswire.com Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel,…
gurufocus.com Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPR News
prnewswire.com Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026…
businesswire.com Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO,…
zacks.com Summit Expands Ivonescimab Development Into Biliary Tract Cancer SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.
businesswire.com Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026…
zacks.com Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
prnewswire.com Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ --…
benzinga.com Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line…
businesswire.com Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate…
businesswire.com Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential…
benzinga.com Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7% Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.
benzinga.com Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway Amazon, Alphabet and Tesla rose Friday, but Robinhood traders sold all three. The monthly data suggests profit-taking, not an AI trade exit.
zacks.com SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
gurufocus.com AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e
businesswire.com AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity…
benzinga.com AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
gurufocus.com Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:- benzinga.com Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer
businesswire.com Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to…
businesswire.com Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to…
benzinga.com Robinhood Traders Just Went on Their Biggest Buying Binge Ever Robinhood traders just recorded their biggest five-day buying binge ever, piling into stocks including FICO, SMMT, MDB and NVTS.
benzinga.com Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20 Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.
defenseworld.net Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – What’s Next? Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $15.48, but opened at $18.91. Summit Therapeutics…
benzinga.com Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
benzinga.com Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43 Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.
benzinga.com AstraZeneca Invests in Summit Therapeutics after Year of Speculation AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
benzinga.com Why Navitas Semiconductor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Navitas jumped 11.8% after winning a U.S. 10kV SiC program; BIO-key led gainers, while NewGenIvf and Knorex plunged in premarket trading.
benzinga.com AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug Conjugates Across Tumour Types; Summit And AstraZeneca Have Also Entered Into A Clinical Collaboration Agreement To Evaluate Sonesitatug Vedotin In Combination With Ivonescimab https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html
benzinga.com HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.- benzinga.com 3 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com Summit Therapeutics Notes That Data From The Phase III HARMONi-GI1 Trial Will Be Presented At The European Society For Medical Oncology Congress, October 23–27 Data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be…
benzinga.com Nasdaq 100 Rallies, Intel Soars 14%: Stock Market Today A fourth straight decline in crude oil handed Wall Street a fresh leg higher Monday, with the Nasdaq 100 jumping to a three-month high as semiconductors led the tape. Intel surged nearly 14% on SK…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented…
benzinga.com Why Is Summit Therapeutics Stock Gaining Monday? Summit partner Akeso reports 30.8-month median OS for ivonescimab vs 22.6 for pembrolizumab in lung cancer trial. SMMT up over 6%.- benzinga.com Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 MonthsPD-L1 High Expression Subgroup: Hazard Ratio =…
benzinga.com Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25 Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.
benzinga.com Wall Street Rallies as Fed’s Waller Hints at September Rate Hold: Stock Market Today Stocks rallied and Treasury yields retreated from three-year highs after Fed Governor Waller signaled he could back a rate hold, sending bitcoin above $80,000.
benzinga.com Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.
benzinga.com Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.